AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type 1 diabetes, hepatitis ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Northwestern Medicine investigators have identified a surprising culprit in the progression of inflammatory bowel disease: a ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...

Sean Dunne, of Shenandoah (Bloomsburg campus); and Adam Seasholtz, Selinsgrove (Lock Haven campus) presented their research ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

Cancer: «forgotten» cells go on the offensive. UNIGE Immunologists have discovered the yet unsuspected anti-tumour potential ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.